Health and Healthcare
What Analysts Are Saying About GoodRx After the Quiet Period
Published:
GoodRx Holdings Inc. (NASDAQ: GDRX) had a very hot initial public last month, but after the excitement settled down analysts started to release their reports on the stock. The post-IPO quiet period is over, and now analysts are rushing to make calls on the stock. For the most part, sentiment seems relatively positive.
The company originally priced its IPO at $33 per share, above the expected price range of $24 to $28. The stock ran up massively on the first day of trading, actually entering the market above $46. However, since then, investors have been relatively undecided on the stock.
Some quick background: GoodRx provides Americans will health care services and prescriptions through its digital platform. Essentially, this platform connects consumers with affordable and convenient health care products and services. These include telehealth, mail-order prescriptions, doctor visits and lab tests. The firm had 4.4 million monthly active consumers and 15 million monthly visitors for the second quarter of 2020.
Shares of GoodRx have reached as high as $64 since the stock came public, but they came crashing back down almost immediately. Many analysts have come out with targets that aren’t nearly this generous.
Here’s what analysts said about GoodRx after the quiet period:
GoodRx stock traded down about 4% on Monday to $50.75, in a post-IPO range of $45.50 to $64.22.
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.